Covid 19 Research using Clinical Trials (Home Page)
HP:0002293: Alopecia of scalpHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug351 | Biological sampling Wiki | 0.71 |
| drug352 | Biological test Wiki | 0.71 |
| drug1935 | Proxalutamide Wiki | 0.71 |
| drug799 | Dutasteride Wiki | 0.71 |
| drug420 | CAG length <22 Wiki | 0.71 |
| drug421 | CAG length >=22 Wiki | 0.71 |
| drug1270 | Ivermectin Wiki | 0.17 |
| drug262 | Azithromycin Wiki | 0.12 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000505 | Alopecia NIH | 1.00 |
| D011470 | Prostatic Hyperplasia NIH | 0.71 |
| D006965 | Hyperplasia NIH | 0.71 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.03 |
Correlated HPO Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0008711 | Benign prostatic hyperplasia HPO | 0.71 |
There are 2 clinical trials
Clinical Trials
1 In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.
NCT04368897 SARS-CoV 2 COVID COVID-19 Androgenetic Alopecia Androgen Receptor Abnormal Androgen Deficiency Diagnostic Test: CAG length <22 Diagnostic Test: CAG length >=22 MeSH:Alopecia
HPO:Alopecia Alopecia of scalp Frontal balding
Primary Outcomes
Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.
Measure: Hospital-free days to Day 28 [ Time Frame: 28 days] Time: 28 days
Description: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and death
Measure: 1. Severity of Disease Time: Day 28
2 Anti-Androgen Treatment for COVID-19
Primary Outcomes
Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.
Measure: Hospital-free days to Day 28 [ Time Frame: 28 days] Time: 28 daysDescription: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and death
Measure: 1. Severity of Disease Time: Day 28This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
NCT04446429 COVID-19 SARS-CoV2 Androgenetic Alopecia Prostate Cancer Benign Prostatic Hyperplasia SARS (Severe Acute Respiratory Syndrome) Drug: Dutasteride Drug: Ivermectin Drug: Azithromycin Drug: Proxalutamide MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Prostatic Hyperplasia Alopecia Hyperplasia
HPO:Alopecia Alopecia of scalp Benign prostatic hyperplasia Frontal balding
Primary Outcomes
Description: Percentage of subjects hospitalized due to COVID-19
Measure: COVID-19 hospitalization Time: 30 days
Description: COVID Ordinal Scale defined as:
Death
Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)
Hospitalized on non-invasive ventilation or high flow nasal cannula
Hospitalized on supplemental oxygen
Hospitalized not on supplemental oxygen
Not hospitalized with limitation in activity (continued symptoms)
Not hospitalized without limitation in activity (no symptoms)
Measure: COVID-19 Ordinal Outcomes Scale Time: 30 days
Secondary Outcomes
Description: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm
Measure: Symptoms severity of COVID-19 Time: 30 days
HPO Nodes
Primary Outcomes
Description: Percentage of subjects hospitalized due to COVID-19
Measure: COVID-19 hospitalization Time: 30 daysDescription: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)
Measure: COVID-19 Ordinal Outcomes Scale Time: 30 daysSecondary Outcomes
Description: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm
Measure: Symptoms severity of COVID-19 Time: 30 days